AORT Q2 Deep Dive: Product Momentum and Pipeline Advances Drive Upgraded Guidance

August 11, 2025 at 09:40 AM EDT

AORT Cover Image

Medical device company Artivion (NYSE: AORT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 15.3% year on year to $113 million. The company’s full-year revenue guidance of $439 million at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $0.24 per share was 92% above analysts’ consensus estimates.

Is now the time to buy AORT? Find out in our full research report (it’s free).

Artivion (AORT) Q2 CY2025 Highlights:

Revenue: $113 million vs analyst estimates of $108.2 million (15.3% year-on-year growth, 4.4% beat)
Adjusted EPS: $0.24 vs analyst estimates of $0.13 (92% beat)
Adjusted EBITDA: $24.76 million vs analyst estimates of $21.1 million (21.9% margin, 17.4% beat)
The company lifted its revenue guidance for the full year to $439 million at the midpoint from $429 million, a 2.3% increase
EBITDA guidance for the full year is $88.5 million at the midpoint, above analyst estimates of $86.63 million
Operating Margin: 7.4%, in line with the same quarter last year
Sales Volumes rose 19.4% year on year (10.9% in the same quarter last year)
Market Capitalization: $1.93 billion

StockStory’s Take

Artivion’s second quarter was marked by significant product momentum, as robust sales of On-X mechanical heart valves and stent grafts drove revenue growth well above Wall Street expectations. Management attributed the quarter’s outperformance to accelerating adoption of the On-X valve—particularly in the U.S.—and the successful initial launch of the AMDS stent graft following FDA approval. CEO Pat Mackin noted, “Our Q2 performance was enabled by continued growth across our product portfolio with exceptional strength in U.S. On-X sales.” Management also highlighted the benefits of cross-selling between new and existing products, and early progress reducing the tissue processing backlog created by last year’s cybersecurity event.

Looking forward, Artivion’s upgraded guidance is underpinned by continued AMDS commercialization, pipeline expansion, and expectations for sustained volume growth across core product lines. Management emphasized that future revenue and profitability gains will be driven by further adoption of the AMDS device, new clinical data supporting On-X valves, and the anticipated launch of pivotal clinical trials for pipeline products like Arcevo. CFO Lance Berry stated, “We expect adjusted EBITDA to be in the range of $86 million to $91 million for the full year 2025, representing a 21% to 28% growth over 2024.”

Key Insights from Management’s Remarks

Management credited strong On-X valve and stent graft sales, the AMDS launch, and operational leverage for driving the quarter’s results and setting up improved full-year guidance.

On-X Valve Acceleration: The On-X mechanical heart valve delivered double-digit growth, supported by new clinical data and expanded use among younger patients under age 65. Management highlighted that positive results from the Journal of the American College of Cardiology and recent marketing efforts have increased awareness and adoption, especially in U.S. hospitals.
AMDS Launch Impact: The U.S. launch of the AMDS stent graft, enabled by recent FDA humanitarian device exemption approval, contributed meaningfully to revenue growth. The device’s simple training requirements and positive physician feedback have accelerated hospital onboarding and initial stocking orders, with management viewing it as a key driver for ongoing expansion.
Cross-Selling Success: Management described a “more profound than expected” cross-selling dynamic, as AMDS training sessions led to increased On-X valve adoption among new customer accounts. This synergy reinforced the company’s multipronged growth strategy and enabled further penetration in top cardiac centers.
Pipeline and Clinical Trial Progress: Artivion advanced its pipeline with FDA investigational device exemption approval to begin a U.S. pivotal trial of the Arcevo frozen elephant trunk device by year-end. The company is also progressing toward premarket approval of the AMDS and tracking positive trial results for the Endospan NEXUS device, which could expand its market reach if acquired.
Operational and Margin Improvements: Margin expansion was attributed to a favorable product mix, particularly from high-margin AMDS and On-X sales, as well as expense discipline and deleveraging via retirement of convertible notes. Management expects further EBITDA margin gains as AMDS scales and sales leverage increases.

Drivers of Future Performance

Artivion’s outlook is anchored by ongoing AMDS adoption, clinical trial milestones, and margin expansion from product mix and operational leverage.

AMDS Commercialization and Pipeline Launches: Management expects sustained momentum from the ongoing rollout of AMDS in the U.S., with cross-selling opportunities and hospital onboarding driving additional growth. The company also highlighted upcoming pivotal trials for Arcevo and anticipated regulatory progress on NEXUS, which could unlock new revenue streams if approved and acquired.
On-X Valve Adoption and Data: Strength in the On-X valve business is expected to continue, fueled by recent clinical evidence favoring mechanical valves for younger patients and ongoing marketing targeting cardiologists. Management believes this will support double-digit growth and further market share gains.
Margin Expansion and Cash Flow Discipline: Artivion aims to expand EBITDA margins through higher sales of premium, high-margin products like AMDS and On-X, while maintaining expense control and leveraging existing sales infrastructure. Risks include any delays in product adoption, regulatory timelines, or macroeconomic headwinds impacting hospital procurement.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the pace of AMDS hospital onboarding and cross-selling effects with On-X valves, (2) progress toward clearing the tissue processing backlog and achieving consistent mid-single-digit growth in that segment, and (3) execution of pivotal clinical trials for Arcevo and progress on NEXUS regulatory milestones. The ability to maintain margin expansion and effective capital deployment will also be key indicators.

Artivion currently trades at $40.73, up from $32.70 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems